KR101073590B1 - Ｉｌ-13에 대한 인간 항체 분자 - Google Patents

Ｉｌ-13에 대한 인간 항체 분자 Download PDF

Info

Publication number
KR101073590B1
KR101073590B1 KR1020067000933A KR20067000933A KR101073590B1 KR 101073590 B1 KR101073590 B1 KR 101073590B1 KR 1020067000933 A KR1020067000933 A KR 1020067000933A KR 20067000933 A KR20067000933 A KR 20067000933A KR 101073590 B1 KR101073590 B1 KR 101073590B1
Authority
KR
South Korea
Prior art keywords
ser
gly
seq
domain
antibody
Prior art date
Application number
KR1020067000933A
Other languages
English (en)
Korean (ko)
Other versions
KR20060054312A (ko
Inventor
필립 데이빗 몽크
루츠 제르무투스
랄프 레이몬드 민터
셀리아 패트리시아 셜록
Original Assignee
메디뮨 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB0407315.1A external-priority patent/GB0407315D0/en
Application filed by 메디뮨 리미티드 filed Critical 메디뮨 리미티드
Publication of KR20060054312A publication Critical patent/KR20060054312A/ko
Application granted granted Critical
Publication of KR101073590B1 publication Critical patent/KR101073590B1/ko

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
KR1020067000933A 2003-07-15 2004-07-15 Ｉｌ-13에 대한 인간 항체 분자 KR101073590B1 (ko)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US48751203P 2003-07-15 2003-07-15
US60/487,512 2003-07-15
US55821604P 2004-03-31 2004-03-31
GBGB0407315.1A GB0407315D0 (en) 2003-07-15 2004-03-31 Human antibody molecules
US60/558,216 2004-03-31
GB0407315.1 2004-03-31
US57379104P 2004-05-24 2004-05-24
US60/573,791 2004-05-24

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020117003966A Division KR101168815B1 (ko) 2003-07-15 2004-07-15 Ｉｌ-13에 대한 인간 항체 분자

Publications (2)

Publication Number Publication Date
KR20060054312A KR20060054312A (ko) 2006-05-22
KR101073590B1 true KR101073590B1 (ko) 2011-10-14

Family

ID=44535047

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020067000933A KR101073590B1 (ko) 2003-07-15 2004-07-15 Ｉｌ-13에 대한 인간 항체 분자

Country Status (8)

Country Link
JP (3) JP5519567B2 (el)
KR (1) KR101073590B1 (el)
AU (1) AU2011200308B2 (el)
CY (1) CY1111467T1 (el)
HK (3) HK1097853A1 (el)
MX (1) MXPA06000258A (el)
NO (2) NO338853B1 (el)
RU (1) RU2009148270A (el)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2016015785A (es) * 2014-06-18 2017-04-25 Medimmune Llc Metodos y medios de cultivo celular que comprenden n-acetilcisteina.

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003035847A2 (en) * 2001-10-26 2003-05-01 Centocor, Inc. Il-13 mutein proteins, antibodies, compositions, methods and uses

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU5010793A (en) * 1992-08-21 1994-03-15 Schering Corporation Human interleukin-13
EP1461428B1 (en) * 2001-12-03 2012-03-21 Alexion Pharmaceuticals, Inc. Method for producing hybrid antibodies
AU2003223497A1 (en) * 2002-04-05 2003-10-27 Centocor, Inc. Asthma-related anti-il-13 immunoglobulin derived proteins, compositions, methods and uses
AU2003260748A1 (en) * 2002-08-30 2004-03-19 Glaxo Group Limited Il-14 vaccine for the treatment of asthma and atopic disorders
GB0407315D0 (en) * 2003-07-15 2004-05-05 Cambridge Antibody Tech Human antibody molecules
TWI307630B (en) * 2004-07-01 2009-03-21 Glaxo Group Ltd Immunoglobulins

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003035847A2 (en) * 2001-10-26 2003-05-01 Centocor, Inc. Il-13 mutein proteins, antibodies, compositions, methods and uses

Also Published As

Publication number Publication date
KR20060054312A (ko) 2006-05-22
HK1155185A1 (zh) 2012-05-11
AU2011200308A1 (en) 2011-02-17
JP2016047843A (ja) 2016-04-07
JP5922686B2 (ja) 2016-05-24
NO342727B1 (no) 2018-07-30
JP2014101372A (ja) 2014-06-05
NO20160707A1 (no) 2016-04-27
NO20060730L (no) 2006-04-10
NO338853B1 (no) 2016-10-24
AU2011200308B2 (en) 2011-07-28
JP5519567B2 (ja) 2014-06-11
CY1111467T1 (el) 2015-08-05
MXPA06000258A (es) 2006-07-03
HK1097853A1 (en) 2007-07-06
HK1216427A1 (zh) 2016-11-11
RU2009148270A (ru) 2011-06-27
JP2011147454A (ja) 2011-08-04

Similar Documents

Publication Publication Date Title
KR101168815B1 (ko) Ｉｌ-13에 대한 인간 항체 분자
US20210147559A1 (en) Antibody molecule for human gm-csf receptor alpha
JP5844315B2 (ja) インターロイキン６に対する結合性メンバー
JP4970258B2 (ja) ヒトインターロイキン−１３に対する抗体およびそれらの使用
KR20090029272A (ko) 인간 ｉｌ-17에 대한 항체 분자
KR101073590B1 (ko) Ｉｌ-13에 대한 인간 항체 분자
AU2007231128B2 (en) Binding member for GM-CSF receptor

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
A107 Divisional application of patent
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20140924

Year of fee payment: 4

FPAY Annual fee payment

Payment date: 20150923

Year of fee payment: 5

FPAY Annual fee payment

Payment date: 20160921

Year of fee payment: 6

FPAY Annual fee payment

Payment date: 20170908

Year of fee payment: 7

FPAY Annual fee payment

Payment date: 20181002

Year of fee payment: 8

FPAY Annual fee payment

Payment date: 20190919

Year of fee payment: 9